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1  | INTRODUCTION
Kisspeptin	 and	neurokinin	B	 (NKB)	 are	hypothalamic	neuropeptides	
now	 recognized	 to	 be	 key	 regulators	 of	 GnRH	 secretion	 and	 thus	
central	 to	 the	 control	 of	 the	 human	 hypothalamo-	pituitary-	gonadal	
(HPG)	axis.1	Men	and	women	with	loss-	of-	function	mutations	in	kis-
speptin,	neurokinin	B	or	their	cognate	receptors	(KISS1R	and	NK3R)	




2  |     SKORUPSKAITE ET Al.
delay,2-5	whilst	activating	mutations	in	the	kisspeptin	receptor	are	as-
sociated	with	precocious	puberty.6
Whilst	 kisspeptin	 potently	 stimulates	 gonadotropin	 secretion	
7-11	 and	 increases	 LH	 pulse	 frequency	 in	 men,9	 the	 effects	 of	 ex-
ogenous	 NKB	 administration	 are	 unclear.	 In	 animal	 studies,	 both	











Kisspeptin	 and	NKB	are	 co-	expressed	by	 some	neurones	within	
the	hypothalamus,	in	humans	and	other	species.	These	neurones	can	
also	 co-	express	 the	 opioid	 dynorphin	 and	 thus	 have	 been	 termed	
KNDy	neurones.20	The	interaction	and	functional	hierarchy	between	
kisspeptin	 and	 neurokinin	 B	 are	 inferred	 from	 observations	 from	
preclinical	 and	clinical	 studies.	Thus	 in	animal	models,	Kissr1 knock-
out	 mice	 were	 unable	 to	 show	 a	 stimulatory	 effect	 of	 the	 NK3R	
agonist	senktide	on	LH	secretion,21	and	in	juvenile	male	monkeys,	kis-












We,	 therefore,	 sought	 to	 determine	whether	NKB	 has	 a	 physi-
ological	 role	 in	 the	 regulation	of	 the	male	 reproductive	 axis	by	 the	
administration	of	 the	specific	NK3R	antagonist	MLE4901,	with	de-
tailed	 analysis	 of	 potential	 effects	 on	 GnRH/LH	 pulsatility,	 and	 to	
explore	the	hierarchy	between	NKB	and	kisspeptin	in	the	control	of	
this	pathway.
2  | MATERIALS AND METHODS
2.1 | Study subjects
Six	 healthy	men,	 aged	 23-	39	years	 were	 recruited	 to	 this	 study;	 all	
volunteers	provided	informed	written	consent	and	the	study	received	
Ethics	Committee	approval.	Subjects	had	normal	physical	examination	




The	 NK3R	 antagonist	 MLE4901	 (previously	 known	 as	 AZD4901,	










2.3.1 | Investigation of the effect of NK3R  
antagonism on gonadotropin and testosterone  
secretion
A	 schematic	 representation	 of	 the	 protocol	 is	 shown	 in	 Figure	1.	
Volunteers	were	administered	the	NK3R	antagonist	for	7	days.	Single	
time	 point	 daily	 peripheral	 venous	 blood	was	 sampled	 for	 LH,	 FSH	





2.3.2 | Investigation of the effect of NK3R 
antagonist on LH pulsatility
On	day	−1	and	on	the	last	day	of	NK3R	antagonist	administration	(day	
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day	7,	 volunteers	 took	 the	NK3R	 antagonist	within	 an	hour	 before	
starting	 the	 pulsatility	 assessment	 blood	 sampling.	 All	 visits	 com-
menced	 between	 08.00	 and	 09.00	hours.	 Blood	 samples	 were	 col-
lected	 via	 an	 indwelling	 intravenous	 cannula	 at	 10-	minute	 intervals	
for	6	hours	for	assessment	of	LH	pulsatility.
2.3.3 | Establishment of the hierarchy between 











until	 analysis.	 LH	 and	 FSH	 were	 measured	 by	 ELISA	 as	 previously	






pared	 using	 one-	way	 analysis	 of	 variance	 (ANOVA)	 with	 repeated	






and	 between	 treatments	were	 performed	 using	 repeated	measures	
two-	way	 ANOVA	with	 Bonferroni’s	 multiple	 comparisons	 post	 hoc	
analysis.	 Paired	 Student’s	 t	 test	 (for	 parametric	 data)	 or	 Wilcoxon	







3.1 | NK3R antagonist decreases gonadotropin and 
testosterone secretion
LH	 secretion	based	on	daily	 LH	values	decreased	during	NK3R	an-
tagonist	 administration	 (P	<	.03),	with	 a	 biphasic	 response:	 LH	 con-
centrations	 were	 significantly	 reduced	 after	 24	hours	 of	 treatment	
(4.5	±	0.6	IU/L	on	day	−1	to	1.7	±	0.2	IU/L	on	day	2,	P	<	.05)	and	then	
recovered	(4.2	±	0.7	IU/L	on	day	4	and	3.7	±	0.7	IU/L	on	day	6)	but	
were	 again	 decreased	 on	 day	 7	 (2.5	±	0.6	IU/L	 vs	 day	 −1,	 P	<	.05)	
(Figure	2A).	To	detect	subtle	changes	in	hormone	secretion	over	time	











are	presented	as	mean	±	SEM.	*P < .05; 
**P	<	.01;	***P	<	.001;	****P < .0001  
vs	day	−1







ministration	 (P	=	.001),	 being	 significantly	 lower	 after	 24	hours	 of	
treatment	 (3.6	±	0.3	 vs	 2.4	±	0.4	IU/L,	 P	<	.001)	 (Figure	2C).	 FSH	







Serum	 testosterone	 recovered	 to	pretreatment	 concentrations	 in	 all	
subjects	2	weeks	later	(19.8	±	2.0	nmol/L).
3.2 | Effect of NK3R antagonist on pulsatile LH 
secretion in men
The	 characteristics	 of	 the	 pulsatile	 secretion	 of	 LH	 were	 deter-
mined	 before	 and	 after	 7	days	 of	 NK3R	 antagonist	 treatment.	 The	
LH	pulse	profile	from	all	individual	subjects	is	shown	in	Figure	3.	LH	
pulse	frequency	was	unchanged	by	NK3R	antagonist	(0.50	±	0.09	vs	
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the	overall	suppression	of	LH	secretion	seen	 in	the	daily	time	point	
analysis,	other	parameters	of	LH	secretion	were	reduced.	Both	basal	
(nonpulsatile)	 and	 pulsatile	 mass	 of	 LH	 secretion	 were	 lower	 with	
NK3R	antagonist	treatment	compared	with	day	−1	(Figure	4B-	C,	both	
P	=	.02).	The	secretory	mass	of	LH	per	pulse	(Figure	4D)	was	not	sig-
nificantly	 changed	 (P	<	.09).	NK3R	antagonist	 increased	 the	orderli-
ness	of	the	LH	secretion	pattern	as	assessed	by	approximate	entropy	
(ApEn)	(P	=	.02;	Figure	4E).
3.3 | NK3R antagonist does not reduce kisspeptin- 
induced LH secretion
To	 assess	 the	 hierarchical	 interaction	 between	 kisspeptin	 and	 neu-
rokinin	 B	 in	 the	 regulation	 of	 LH	 secretion	 in	men,	 an	 intravenous	
bolus	 injection	 of	 kisspeptin-	10	 was	 administered	 after	 6	hours	 of	
blood	 sampling	on	day	−1	and	on	day	7	of	NK3R	antagonist	 treat-
ment	(Figure	5).	Kisspeptin-	10	elicited	a	rapid	increase	in	LH	concen-
tration	(3.0	±	0.6	at	6	hours	vs	4.8	±	0.5	IU/L	at	7	hours,	P < .05 and 









istration	 suggested	 an	 enhanced	 response	 during	 NK3R	 antagonist	
treatment	 (kisspeptin-	10	 alone	ΔAUC	 LH	 7	 and	 8	hours:	 2.5	±	0.2	
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Pharmacological	blockade	of	NKB-	NK3R	signalling	caused	a	rapid	and	























Sustained	 suppression	 of	 testosterone	 secretion	was	 observed	






pattern	of	LH	pulsatility.	 It	 is	possible	 that	 recovery	of	 suppressed	
LH	 secretion	whilst	 testosterone	 levels	 remain	 low	 on	 days	 4	 and	





although	 caution	 must	 be	 taken	 when	 interpreting	 those	 findings	
given	that	once	only	daily	blood	sampling	may	miss	subtle	changes	in	
hormone	secretion	especially	when	there	are	relatively	rapid	changes	
in	 steroid	 feedback	 and	 the	 pathways	 that	mediate	 that	 feedback	
are	 likely	 to	 be	 impacted	 by	 this	 drug.	Nevertheless,	 analysis	 over	
6	hours	after	dosing	on	day	7	showed	consistent	suppression	of	LH	
suggesting	that	suppression	would	persist	with	chronic	antagonism	
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studies,	 in	 particular	 the	 demonstration	 that	 kisspeptin-	10	 infusion	
restored	 pulsatile	 LH	 secretion	 in	men	 and	women	with	 inactivating	
mutations	in	neurokinin	B	pathway22 and in normal women in a model 























rokinin	 B	 on	modulating	 GnRH	 secretion	 remains	 unknown.	Whilst	











reflect	 sexual	dimorphism.	However,	 the	 sample	 size	 is	 small,	 and	a	
placebo	 control	 was	 not	 employed	 in	 this	 mechanistic	 exploratory	
study.
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